SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer

Sponsor
The First People's Hospital of Lianyungang
Study ID
NCT06476093
Status
Recruiting
Apply to this trial

Conditions

  • Brain Metastases
  • Non-Small-Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • Anlotinib hydrochloride — DRUG
    Anlotinib#12mg#PO#Q3W#d1-14# SRT#depends

Study Details

To evaluate the efficacy and safety of SRT combined with anlotinib in the treatment of limited brain metastases from non-small cell lung cancer.

Key Dates

First listed
Jun 26, 2024
Start date
Jul 1, 2024
Status verified
Jun 2024
Primary completion
Dec 31, 2026
Completion
Feb 28, 2027

Study Design

Enrollment
46 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Anlotinib+SRT Group
    Anlotinib#12mg#PO#Q3W#d1-14#

Primary Outcome Measure

intracerebral Progression-Free-Surviva（iPFS） [ Time Frame: 20 months ]

Central Contacts

Related Studies